As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...
Stanford University researchers developed a machine learning-based method capable of diagnosing multiple diseases using B ...
The use of next-generation sequencing (NGS) technologies to detect B-cell receptor (BCR) or T-cell receptor (TCR) clonotypes ...
Receptors on B and T cells hint at what the immune system is targeting. An AI approach called Mal-ID developed increases diagnostic accuracy, particularly for autoimmune diseases. Your immune system ...
A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results